NASDAQ:RCKT

Rocket Pharmaceuticals (RCKT) Stock Forecast, Price & News

$20.40

-0.44 (-2.11%)

(As of 09/22/2023 ET)

Compare

Today's Range: $20.13
▼
$21.16
50-Day Range: $15.07
▼
$24.05
52-Week Range: $11.78
▼
$24.65

Volume: 847,180 shs
Average Volume: 2.24 million shs
Market Capitalization: $1.64 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $49.45

Rocket Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 142.4% Upside
$49.45 Price Target
Short Interest: Bearish
8.99% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: 0.46
Based on 4 Articles This Week
Insider Trading: Selling Shares
$108,381 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.15) to ($2.74) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

143rd out of 968 stocks

Pharmaceutical Preparations Industry

43rd out of 442 stocks

3.5

Analyst's Opinion

Consensus Rating
Rocket Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $49.45, Rocket Pharmaceuticals has a forecasted upside of 142.4% from its current price of $20.40.
Amount of Analyst Coverage
Rocket Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.99% of the outstanding shares of Rocket Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.
Change versus previous month
Short interest in Rocket Pharmaceuticals has recently decreased by 6.22%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Rocket Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Rocket Pharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Rocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Rocket Pharmaceuticals is -0.81.

1.9

News and Social Media Coverage

News Sentiment
Rocket Pharmaceuticals has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Rocket Pharmaceuticals this week, compared to 9 articles on an average week.
Search Interest
Only 16 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.
MarketBeat Follows
18 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $108,381.00 in company stock.
Percentage Held by Insiders
31.10% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
94.49% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($3.15) to ($2.74) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rocket Pharmaceuticals is -6.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rocket Pharmaceuticals is -6.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rocket Pharmaceuticals has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.

RCKT Price History

30 days | 90 days | 365 days | Advanced Chart

RCKT Stock News Headlines

September 21, 2023 | finance.yahoo.com

Institutional investors are Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) biggest bettors and were rewarded after last week's US$272m market cap gain

September 18, 2023 | finance.yahoo.com

Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread Carefully

September 23, 2023 | MarketBeat Internal (Ad)

MarketBeat's Top 5 Stock Picks - Just Released

MarketBeat has just released five new trading ideas to All Access subscribers, but Tesla, Apple, and Netflix didn't make the cut. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. Now, MarketBeat thinks these five stocks may be even better buys.

September 16, 2023 | americanbankingnews.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Expected to Post Q3 2023 Earnings of ($0.65) Per Share

September 15, 2023 | finance.yahoo.com

Here's Why Rocket Pharmaceuticals (RCKT) Rises 53.8% in a Week

September 15, 2023 | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Given New $53.00 Price Target at Needham & Company LLC

September 15, 2023 | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Earns "Buy" Rating from Stifel Nicolaus

September 15, 2023 | americanbankingnews.com

FY2025 EPS Estimates for Rocket Pharmaceuticals, Inc. Lowered by Leerink Partnrs (NASDAQ:RCKT)

September 23, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

September 14, 2023 | theglobeandmail.com

Betting on Rocket Pharmaceuticals (RCKT)? Check the Options Flow Data First.

September 13, 2023 | proactiveinvestors.com

Rocket Pharmaceuticals stock takes flight on FDA agreement

September 13, 2023 | markets.businessinsider.com

What's Going On With Gene Therapy-Focused Rocket Pharmaceuticals Stock Today?

September 13, 2023 | investorplace.com

Why Is Rocket Pharmaceuticals (RCKT) Stock Up 35% Today?

September 13, 2023 | markets.businessinsider.com

Analyst Expectations for Rocket Pharmaceuticals's Future

September 13, 2023 | finance.yahoo.com

These Stocks Are Moving the Most Today: Apple, Ford, NIO, Moderna, BP, Rocket Pharmaceuticals, and More

September 12, 2023 | marketwatch.com

Rocket Pharmaceuticals Reaches FDA Alignment in Danon Heart Disease Treatment Trial

September 12, 2023 | marketwatch.com

Rocket Pharmaceuticals Stock Surges 34% on FDA Alignment for Danon Disease Treatment

September 12, 2023 | msn.com

Trans-Siberian Orchestra returns to Cleveland's Rocket Mortgage FieldHouse for 2 shows in December

September 11, 2023 | msn.com

Star Arkansas RB Raheim "Rocket" Sanders Will Not Play Against BYU

September 10, 2023 | usnews.com

Israeli Military Says Failed Rocket Launch Attempt Made From West Bank

September 7, 2023 | technews.tmcnet.com

Leading Industrial Instrumentation, Controls Automation, and Electrical (ICE) provider Selects Revenue Rocket to facilitate a business combination

September 7, 2023 | msn.com

Ranking the NHL’s Rocket Richard contenders ahead of 2023-24 season

September 4, 2023 | usnews.com

Japan's Mitsubishi Heavy Reschedules Moon Rocket Launch for Thursday

September 2, 2023 | sports.yahoo.com

Rocket Sanders’ second touchdown closes first half against Western Carolina

August 31, 2023 | msn.com

Geaux Rocket Ride installed as slight favorite for Saturday’s Pacific Classic at Del Mar

August 29, 2023 | sports.yahoo.com

Bell has all the respect for KJ and Rocket; so does Rutledge

August 29, 2023 | usnews.com

What Makes Idalia So Potent? It's Feeding on Intensely Warm Water That Acts Like Rocket Fuel

See More Headlines

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Company Calendar

Last Earnings: 8/10/2023
Today: 9/23/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RCKT
CUSIP: N/A
CIK: 1281895
Web: www.rocketpharma.com
Phone: (609) 659-8001
Fax: 646-224-9585
Employees: 240
Year Founded: 2018

Price Target and Rating

Average Stock Price Forecast: $49.45
High Stock Price Forecast: $75.00
Low Stock Price Forecast: $34.00
Forecasted Upside/Downside: +142.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-221,860,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -57.83%
Return on Assets: -51.09%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 9.09
Quick Ratio: 9.09

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.47 per share
Price / Book: 3.15

Miscellaneous

Outstanding Shares: 80,530,000
Free Float: 55,482,000
Market Cap: $1.64 billion
Optionable: Optionable
Beta: 1.16

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Gaurav D. Shah M.D. (Age 48)
CEO & Director
Comp: $1.05M

Ms. Kinnari Patel M.B.A. (Age 44)
MBA, Pharm.D., PharmD, Pres & COO
Comp: $849.93k

Mr. John C. Militello CPA (Age 50)
CPA, VP, Sr. Controller, Treasurer, Principal Accounting Officer & Interim Principal Financial Officer
Comp: $501.42k

Mr. Mayo Pujols (Age 54)
Chief Technical Officer & Exec. VP
Comp: $649.71k

Mr. Raj Prabhakar M.B.A. (Age 49)
Sr. VP & Chief Bus. Officer
Comp: $619.13k

Mr. Martin Louis Wilson J.D. (Age 47)
Gen. Counsel, Chief Compliance Officer & Sr. VP

Kevin Giordano
Director of Corp. Communications

Ms. Isabel Carmona J.D.
Sr. VP & Chief HR Officer

Mr. Jonathan Schwartz M.D. (Age 58)
Chief Gene Therapy Officer & Sr. VP of Clinical Devel.

Dr. Gayatri R. Rao J.D.
M.D., Chief Devel. Officer of LVV & Sr. VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RCKT Stock - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings or view top-rated stocks.
What is Rocket Pharmaceuticals' stock price forecast for 2023?: 12 brokers have issued 1 year price targets for Rocket Pharmaceuticals' shares. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they expect the company's share price to reach $49.45 in the next year. This suggests a possible upside of 142.4% from the stock's current price.
View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts.
How have RCKT shares performed in 2023?: Rocket Pharmaceuticals' stock was trading at $19.57 at the start of the year. Since then, RCKT stock has increased by 4.2% and is now trading at $20.40.
View the best growth stocks for 2023 here.
When is Rocket Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our RCKT earnings forecast.
How were Rocket Pharmaceuticals' earnings last quarter?: Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by $0.01. During the same period in the prior year, the company earned ($0.83) earnings per share.
What ETFs hold Rocket Pharmaceuticals' stock?: ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Harbor Health Care ETF (MEDI), Harbor Disruptive Innovation ETF (INNO) and Putnam BioRevolution ETF (SYNB).Franklin Genomic Advancements ETF (HELX).

What other stocks do shareholders of Rocket Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).
What is Rocket Pharmaceuticals' stock symbol?: Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."
Who are Rocket Pharmaceuticals' major shareholders?: Rocket Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.38%), State Street Corp (3.95%), Goldman Sachs Group Inc. (1.79%), Dimensional Fund Advisors LP (1.66%), Geode Capital Management LLC (1.47%) and Perceptive Advisors LLC (1.45%). Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends.
How do I buy shares of Rocket Pharmaceuticals?: Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Rocket Pharmaceuticals' stock price today?: One share of RCKT stock can currently be purchased for approximately $20.40.
How much money does Rocket Pharmaceuticals make?: Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.64 billion. The biotechnology company earns $-221,860,000.00 in net income (profit) each year or ($3.34) on an earnings per share basis.
How many employees does Rocket Pharmaceuticals have?: The company employs 240 workers across the globe.
How can I contact Rocket Pharmaceuticals?: Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (609) 659-8001, via email at investors@rocketpharma.com, or via fax at 646-224-9585.

This page (NASDAQ:RCKT) was last updated on 9/23/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Rocket Pharmaceuticals (RCKT) Stock Forecast, Price & News

Rocket Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

RCKT Price History

RCKT Stock News Headlines

RCKT Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

RCKT Stock - Frequently Asked Questions

Overall MarketRank^™